The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | 2 years on: Deborah discusses her venetoclax trial and becoming MRD negative
Deborah Henderson, chronic lymphocytic leukemia (CLL) patient advocate and journalist, and her doctor John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci meet up during the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 held in New York, NY to discuss Deborah’s current CLL status. Two years after they first met, Deborah is now minimal residual disease (MRD) negative after taking part in a clinical trial (NCT01685892) of venetoclax in combination with obinutuzumab that was recommended to her by Prof. Gribben. The pair talk about Deborah’s treatment journey and experience so far, the importance of patient-doctor communication and touch on the idea of a future cure for CLL.
